Shuttle Pharmaceuticals Holdings (SHPH) EBITDA (2021 - 2026)

Shuttle Pharmaceuticals Holdings' EBITDA history runs 6 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• On a quarterly basis, EBITDA rose 24.89% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 20.73% decrease from a year earlier, with the FY2025 full-year figure at -$11.9 million, down 54.84% from the prior year.
• EBITDA improved to -$2.2 million in Q1 2026 per SHPH's latest filing, from -$2.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$353626.0 in Q2 2022 and bottomed at -$3.9 million in Q2 2025.
• The 5-year median for EBITDA is -$1.5 million (2023), against an average of -$1.8 million.
• Across the five-year window, EBITDA jumped 46.35% in 2022 and plunged 314.46% in 2023, its largest moves.
• Year by year, EBITDA stood at -$530336.0 in 2022, then sank by 141.89% to -$1.3 million in 2023, then tumbled by 38.53% to -$1.8 million in 2024, then sank by 56.9% to -$2.8 million in 2025, then grew by 20.49% to -$2.2 million in 2026.
• Per Business Quant, the three latest SHPH EBITDA figures stand at -$2.2 million (Q1 2026), -$2.8 million (Q4 2025), and -$2.3 million (Q3 2025).